Sign In
Buy GSK
$51.53
+0.0200 (+0.0388%)
At Close: Aug 04, 2026
GSK plc (GSK) Q2 2025 Earnings Call Transcript
05:56pm, Wednesday, 30'th Jul 2025
GSK plc (NYSE:GSK ) Q2 2025 Earnings Conference Call July 30, 2025 7:00 AM ET Company Participants Deborah Jayne Waterhouse - CEO of ViiV Healthcare & President of Global Health Emma Natasha Walmsley
GSK Beats on Q2 Earnings & Sales, Stock Gains on '25 Outlook Raise
12:46pm, Wednesday, 30'th Jul 2025
GSK's Q2 earnings and revenues top forecasts, with Specialty Medicines and Vaccines driving growth and a raised 2025 outlook boosting shares.
GSK CEO: Innovation is the secret to bringing down cost of overall healthcare
11:32am, Wednesday, 30'th Jul 2025
Emma Walmsley, GSK CEO, joins CNBC's 'Squawk on the Street' to discuss the company's most recent earnings, innovation pipeline, the potential impact of tariffs on pharmaceuticals, and much more.
GSK may have numbers may have been flattered by order timing, says bank
10:49am, Wednesday, 30'th Jul 2025
GSK PLC (LSE:GSK, NYSE:GSK) delivered a strong set of second-quarter results, beating expectations on sales, profits, and earnings per share, and raised its guidance to the top end of its previous ra
GSK (GSK) Q2 Earnings and Revenues Beat Estimates
08:06am, Wednesday, 30'th Jul 2025
GSK (GSK) came out with quarterly earnings of $1.23 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $1.09 per share a year ago.
GSK in talks with Trump administration on U.S. drug pricing, CEO says
05:26am, Wednesday, 30'th Jul 2025
British drugmaker GSK said on Wednesday it is in talks with the Trump administration about ways to lower U.S. drug costs, becoming the latest pharmaceutical company to acknowledge action under pressur
GSK confident of hitting top end of 2025 targets after strong second quarter
02:57am, Wednesday, 30'th Jul 2025
GSK PLC (LSE:GSK, NYSE:GSK) said on Wednesday it expects to deliver results at the top end of its guidance for the year after reporting a robust second quarter, fuelled by strong sales in its Special
GSK expects annual sales and profit at top end of forecast range
02:12am, Wednesday, 30'th Jul 2025
British drugmaker GSK said on Wednesday it expects to report annual sales and profit towards the top end of its forecast range, adding that its outlook includes the impact of tariffs in place so far a
GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval
12:41pm, Monday, 28'th Jul 2025
GSK's diversified portfolio and strong HIV/specialty medicines offer stability, but growth prospects remain modest amid stiff competition and legal overhangs. Despite a robust pipeline and management'
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSK
11:47am, Monday, 28'th Jul 2025
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK). Such investors are advised to contac
GSK shares rise on $500m drug deal with China's Hengrui
06:39am, Monday, 28'th Jul 2025
Shares in GSK PLC (LSE:GSK, NYSE:GSK) rose in morning trading after the pharmaceutical group announced a $500 million collaboration with Hengrui Pharma to co-develop up to 12 experimental medicines,
GSK to make $500m down payment on Chinese licensing deal worth up to $12bn
02:49am, Monday, 28'th Jul 2025
GSK PLC (LSE:GSK, NYSE:GSK) has agreed to pay $500 million in upfront fees to Chinese drugmaker Hengrui Pharma as part of a wide-ranging collaboration to develop up to 12 experimental medicines in a
Jiangsu Hengrui grants GSK global rights to drug portfolio in $500 million deal
10:35pm, Sunday, 27'th Jul 2025
China's Jiangsu Hengrui Pharmaceuticals said on Monday it has agreed to license the global rights of its HRS-9821 drug and 11 other programmes to GlaxoSmithKline Intellectual Property (GSK) for $500 m
Includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPD Additional 11 programmes to be developed by Hengrui Pharma and optioned by GSK fo
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK
10:00am, Sunday, 27'th Jul 2025
NEW YORK , July 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc ("GSK" or the "Company") (NYSE: GSK). Such investors are advised to contact Danielle P
